Estudio a 2 años para medir la eficacia del fentanilo intranasal en pectina en el dolor irruptivo en enfermos con dolor no oncológico de edad avanzada

Abstract

Patients with moderate-to-severe pain in non-cancer conditions usually receive opioids for pain control. Many of these patients also suffer breakthrough pain, with the same characteristics as cancer pain. Their breakthrough pain is mainly related to wandering and walking, which in this study we treated with fentanyl pectin nasal spray. The study initially included 22 elderly patients (20 men and 2 women) with non chronic cancer pain with a mean age of 74.7 (60-88) years in a 24 month follow-up. Lack of problems of abuse of these drugs was confirmed probably by the proper selection of patients and health education that enabled them to distinguish exacerbations of their baseline pain from the breakthrough pain episodes and its specific treatment. Fentanyl pectin nasal spray showed good tolerability, and improved in more than 4 points relief of breakthrough pain due to wandering and walking, also improved quality of life and sleep in our 24 months study in non-cancer patients.